ReCor Medical develops the Paradise ultrasound renal denervation (RDN) system and is based in Palo Alto and Amsterdam. Paradise has CE Mark approval in the European Union and has been tested in three clinical trials involving more than 200 patients. The company emphasizes its ultrasound approach may offer advantages over radiofrequency systems by providing active vessel protection and 360° energy delivery. ReCor plans to pursue a U.S. clinical trial of Paradise and has engaged with the FDA on study design. Management stated they aim to finalize the clinical study design and begin patient enrollment in the second half of 2015. The recent funding is intended to support those clinical activities.

Total raised

$15M

Funding rounds

1

Latest round

Series D

Latest activity

Apr 2015